Ofra Barchad-Avitzur

MedicineBiochemistry, Genetics and Molecular BiologyImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation”.

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation

Journal of Cystic Fibrosis(2021)10.1016/j.jcf.2021.06.003

N/A

1.6DataRank · unranked

53 citations

Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao +13 more

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.02.14.431123

N/A

0.241DataRank · unranked

4 citations

Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao +11 more

236 SPL84, an antisense oligonucleotide modulating the 3849+10 kb C-T splicing defect, efficiently penetrates and restores CFTR function when treated through the apical side of primary human bronchial epithelial cells

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01166-9

N/A

0DataRank · unranked

0 citations

Yifat S. Oren, C. Stampfer, E. Ozeri-Galai, Gili Hart, Batsheva Kerem +1 more